


ATTY. DOCKET:UCIVN-035A
Serial No. 10/810,497

This listing of claims will replace all prior versions, listing, of all claims in the application:

What is claimed is:

1. (Withdrawn) A method for inducing CD81 dependent antiproliferation in a human or veterinary patient, said method comprising the step of:

(A) administering to the patient a therapeutically effective amount of an amantadine analogue having the formula:



wherein,

X is Boron or Carbon;


A is NH and NHR₁, where R₁ is H, alkyl or imino-alkyl amino;

Z is a acyclic or cyclic, saturated or unsaturated, chiral or achiral, straight or branched hydrocarbyl group with from 1 to 10 carbon atoms, C=O, SO₂, or absent; and R is an acyclic or cyclic, saturated or unsaturated, chiral or achiral, straight or branched hydrocarbyl group with from 1 to 20 carbon atoms and -CH-R₂R₃ -CHR₂R₃, wherein R₂ is selected from aryl, substituted aryl, heteroaryl, substituted heteroaryl, (CH₂)_n-Q, where n is 1-4 and Q is BSH, -OH, -NH₂, -NH-CO-NH₂, -NH-C=(NR₄) NHR₅, -COOH and its alkyl esters, and -CONH₂ and R₄ and R₅ are H, C₁-C₄ alkyl or R₄ and R₅ may combine to form a cyclic ring, R₂ and A may combine to form a cyclic ring; R₃ is carboxyl, its alkyl esters, carboxamide or substituted carboxamide, sulfonic acid, sulfonate esters, sulfonamide, substituted sulfonamide, phosphonic and phosphoric acids and their alkyl esters.

ATTY. DOCKET:UCIVN-035A
Serial No. 10/810,497

2. (Withdrawn) A method according to No. 1 wherein the method is carried out to prevent or treat Hepatitis C.

3. (Presently Amended) A composition of matter having the formula:
~~A method for inducing CD81 dependent antiproliferation in a human or veterinary patient, said method comprising the step of:~~
~~(A) administering to the patient a therapeutically effective amount of an amantadine analogue having the formula:~~



wherein,


X is Boron or Carbon;

A is NH and NHR₁, where R₁ is H, alkyl or imino-alkyl amino;


Z is a acyclic or cyclic, saturated or unsaturated, chiral or achiral, straight or branched hydrocarbyl group with from 1 to 10 carbon atoms, C=O, SO₂, or absent; and R is an acyclic or cyclic, saturated or unsaturated, chiral or achiral, straight or branched hydrocarbyl group with from 1 to 20 carbon atoms or and -CH-R₂R₃, wherein R₂ is selected from aryl, substituted aryl, heteroaryl, substituted heteroaryl, (CH₂)_n-Q, where n is 1-4 and Q is BSH, -OH, -NH₂, -NH-CO-NH₂, -NH-C=(NR₄) NHR₅, -COOH and its alkyl esters, and -CONH₂ and R₄ and R₅ are H, C₁₋₄ alkyl or R₄ and R₅ may combine to form a cyclic ring, R₂ and A may combine to form a cyclic ring; R₃ is carboxyl, its alkyl esters, carboxamide or substituted carboxamide, sulfonic acid, sulfonate esters, sulfonamide, substituted sulfonamide, phosphonic and phosphoric acids and their alkyl esters.

ATTY. DOCKET:UCIVN-035A
Serial No. 10/810,497

4. (New) A composition according to claim 3 having the formula:




5. (New) A composition according to claim 3 having the formula:




ATTY. DOCKET:UCIVN-035A
Serial No. 10/810,497

6. (New) A composition according to claim 3 having the formula:




7. (New) A composition according to claim 3 having the formula:



ATTY. DOCKET:UCIVN-035A
Serial No. 10/810,497

8. (New) A composition according to claim 3 having the formula:



9. (New) A composition according to claim 3 having the formula:

